Thalamus Acquisition of Medicratic FAQs
On July 30, 2025, Thalamus announced the acquisition of Medicratic, a healthcare technology company advancing residency and fellowship application evaluation using artificial intelligence (AI). We’re excited to welcome Medicratic into the Thalamus community. As two teams deeply rooted in graduate medical education (GME), we’re combining our efforts to better serve program directors, coordinators, faculty, and applicants.
This page addresses key questions about product integration, support, and what this means for current and future users of both platforms. We’re excited to share the roadmap ahead, and to continue building tools that help pair the right physicians with the right training environments.
Thalamus has acquired Medicratic to combine our strengths in AI-driven holistic application assessment and to better serve the GME community. By bringing our teams, technology, and visions together, we aim to deliver seamless, data-driven insights for applicants, programs, and institutions.
This acquisition enables Thalamus to accelerate its roadmap in AI, analytics, and holistic review. Medicratic brings GME-specific evaluation systems and structured review workflows that are synergistic with Thalamus’s industry-leading platform. Our combined commitment to technology-assisted holistic review includes enhanced data and analytics to support the transitions to residency and fellowship.
Medicratic is a mission-driven technology company dedicated to transforming the residency and fellowship application review process through intelligent automation and evidence-based evaluation. Its flagship platform, Halsted, enables residency programs to conduct faster, fairer, and more holistic recruitment by leveraging AI-assisted analysis of application materials. Halsted empowers faculty and program leadership to define and prioritize selection criteria, driving more consistent, structured evaluations across committees and cohorts. By reducing administrative burden and mitigating subjectivity, Halsted standardizes review processes, supports equitable decision-making, and delivers real-time insights into applicant pools.
The Medicratic team is joining Thalamus. Founder, Alexander Thomson, MS and Co-Founder and CTO, Ryan Elder, MS will take on roles within Thalamus’s product and infrastructure teams, as Product Manager, AI andSecurity Engineer respectively. Co-Founder and CEO, Tanner Mitton, MD, MBA will become an advisor to Thalamus while beginning his residency training. The team’s continued involvement ensures continuity and preserves the innovative spirit behind Medicratic.
Our combined solution will leverage enhanced technologies to simplify recruitment, increase access to data, and help programs focus on recruiting mission-aligned applicants, ultimately improving outcomes for programs and applicants.
No, there will be no immediate changes. Your current Thalamus workflows, tools, and contracts remain unchanged. Over time, you will gain access to additional capabilities powered by Medicratic’s technology.
We will be integrating key Medicratic/Halsted features into the Thalamus platform over the coming months and beyond. We’ll notify the community when new functionality is available and offer onboarding and support resources.
Yes, as Medicratic features are integrated into the Thalamus platform, it is anticipated that these features will be offered complimentary to Electronic Residency Application Service (ERAS)-participating residency and fellowship programs as part of the collaboration with the Association of American Medical Colleges (AAMC). Additional paid offerings may also be available.
No, all Thalamus data privacy, security, and compliance standards remain in effect.
To focus on integration efforts, we will only be offering Medicratic as a standalone platform to programs that used the system previously.
Yes, in the near term (i.e. 2026 ERAS residency recruitment cycle starting September 2025), Medicratic/Halsted will continue to be offered to paid accounts. The founders of Medicratic will be joining Team Thalamus and will continue to support products and services going forward.
In the future, many features will be integrated into the Thalamus platform. It is anticipated Medicratic’s Halsted product will be sunset as a standalone service. This will be communicated further to the GME community as decisions are made.
Existing Medicratic accounts will continue to function as usual during the transition. We will communicate future timelines, upgrades, and support options in advance of all integration efforts.
Yes. Medicratic customers can still contact support@medicratic.com for all questions and need for technical and/or other support. Over time, these efforts will be merged with Thalamus' Customer Care team to ensure unified assistance.
Thalamus will continue to offer Medicratic for the upcoming 2026 ERAS residency recruitment cycle (starting September 2025) to all paid accounts, including those on multi-year contracts and/or pre-paid for the services. Our team will be in touch regarding options for all programs involved, including the possibility of refunds where applicable.
Programs with paid Medicratic subscriptions will be contacted individually for information regarding billing, support and other services going forward.
Initially, yes. We are actively working to consolidate access through single sign-on (SSO) and unified logins as Medicratic is integrated into Thalamus products.
You’ll benefit from the most seamless experience as we integrate Medicratic into Thalamus. We’ll be reaching out to dual users as a priority for early access to new features and beta opportunities.
We are currently assessing technical pathways to integrate key Medicratic features into the Thalamus Platform. Our goal is to offer some key features for the 2026 ERAS residency recruitment cycle, beginning September 2025. We are targeting a fully unified experience by the 2027 ERAS season (starting July 2026) for all ERAS-participating residency and fellowship programs.
Medicratic’s capabilities are anticipated to enhance Thalamus’s Cortex and Cerebellum platforms. Users can expect new features and deeper insights into reviewer behavior and program outcomes in the coming months.
Yes. We are building tools to help programs forecast applicant alignment, anticipate specialty trends, and optimize recruitment strategies using AI-powered dashboards.
Yes! As always, we’re looking for champions and advisors to help shape the next generation of GME technology. Please contact us at customercare@thalamusgme.com if you're interested in participating.
Thalamus is committed to the AAMC’s Principles for Responsible Use of Artificial Intelligence in and for Medical Education. All AI/ML development always has and will continue to align with our public benefit mission and undergo ethical review. We design technology to augment—not replace—human judgment, and prioritize transparency, fairness, and data stewardship aligned with all applicable laws.
Thalamus and Medicratic both use enterprise level AI-technologies with contractual agreements supporting private cloud environments, such as on Microsoft Azure and ChatGPT. As such, these systems are not training on any applicant or program data. All training on Thalamus (and Medicratic) internal models are aligned with organizational policies and user agreements, and in compliance with all privacy and regulatory standards. Should you have any questions, please contact us at privacy@thalamusgme.com.
%201.svg){kind=icon}